Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Take Tell Us What YOU Think! Take The Body's Visitor Survey!
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

World Trade Organization Generic Drug Deal Not Being Implemented, Leaving Developing Countries Without Antiretrovirals, UNAIDS Says

July 7, 2004

Some countries have not taken steps to implement a World Trade Organization agreement that allows developing countries to waive patent laws to import generic drugs, including antiretroviral drugs, UNAIDS Executive Director Peter Piot said, Reuters reports (Reuters, 7/6). WTO negotiators in August 2003 reached an agreement to allow developing countries to issue a compulsory license in order to import generic drugs if the country confirms that it cannot domestically manufacture them (Kaiser Daily HIV/AIDS Report, 5/24). Only Mozambique, Malaysia and Canada have adopted legislation to implement the agreement, Piot said on Tuesday (Reuters, 7/6). The Canadian Parliament in May adopted a bill (C-9) that would would amend the country's patent laws to permit the government to order the override of patents to allow certain pharmaceutical manufacturers to produce and export generic drugs -- including antiretrovirals -- for use in developing countries (Kaiser Daily HIV/AIDS Report, 5/13). Although the price of antiretrovirals in developing countries has decreased by more than 90%, only 440,000 of the six million people in the developing world that need treatment have access to the drugs, Reuters reports. Piot also said that it is important to ensure that the quality of generic antiretroviral drugs matches that of brand-name drugs. "We don't only want and need cheap drugs, we need top quality medicines," Piot said, adding, "There is no compromise possible on quality ... that would be immoral" (Reuters, 7/6).

Online The San Francisco Chronicle on Wednesday profiled Indian pharmaceutical company Cipla, which produces the generic fixed-dose combination antiretroviral Triomune and other antiretrovirals (Russell, San Francisco Chronicle, 7/7). Triomune combines three different medicines into one pill that is taken twice a day and costs as little as $140 per person per year (Kaiser Daily HIV/AIDS Report, 4/29). The full article is available online.

Back to other news for July 7, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report.
 
See Also
More HIV News

 

Advertisement